Impact of preoperative [18F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer: a 10-year follow-up study

[1] Forde PM(2022)Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer N Engl J Med 386 1973-1985

[2] Spicer J(2017)Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non–small-cell lung cancers: american society of clinical oncology/cancer care ontario clinical practice guideline update J Clin Oncol 35 2960-2974

[3] Lu S(2018)Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Lancet Oncol 19 139-148

[4] Provencio M(2008)Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 3552-3559

[5] Mitsudomi T(2021)Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial Lancet (London, England). 398 1344-1357

[6] Awad MM(2020)Osimertinib in resected EGFR-mutated non-small-cell lung cancer N Engl J Med 383 1711-1723

[7] Kris MG(2022)Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Lancet Oncol 23 1274-1286

[8] Gaspar LE(2015)2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer Ann Oncol 26 1573-1588

[9] Chaft JE(2015)Definitive and adjuvant radiotherapy in locally advanced non–small-cell lung cancer: american society of clinical oncology clinical practice guideline endorsement of the american society for radiation oncology evidence-based clinical practice guideline J Clin Oncol 33 2100-2105

[10] Kennedy EB(2016)Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer Eur J Nucl Med Mol Imaging 43 2084-2097

[1] Forde PM(2022)Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer N Engl J Med 386 1973-1985

[2] Spicer J(2017)Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non–small-cell lung cancers: american society of clinical oncology/cancer care ontario clinical practice guideline update J Clin Oncol 35 2960-2974

[3] Lu S(2018)Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Lancet Oncol 19 139-148

[4] Provencio M(2008)Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 3552-3559

[5] Mitsudomi T(2021)Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial Lancet (London, England). 398 1344-1357

[6] Awad MM(2020)Osimertinib in resected EGFR-mutated non-small-cell lung cancer N Engl J Med 383 1711-1723

[7] Kris MG(2022)Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Lancet Oncol 23 1274-1286

[8] Gaspar LE(2015)2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer Ann Oncol 26 1573-1588

[9] Chaft JE(2015)Definitive and adjuvant radiotherapy in locally advanced non–small-cell lung cancer: american society of clinical oncology clinical practice guideline endorsement of the american society for radiation oncology evidence-based clinical practice guideline J Clin Oncol 33 2100-2105

[10] Kennedy EB(2016)Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer Eur J Nucl Med Mol Imaging 43 2084-2097